The FDA approved the first generic version of Narcan, a nasal spray intended to reverse opioid overdoses.
The generic version of naloxone nasal spray, manufactured by Teva Pharmaceuticals, can be used in a community setting by individuals without medical training.
The approval, granted April 19, is part of the FDA's effort to combat the nationwide opioid crisis.
The generic approval means there could soon be a generic alternative to Narcan, a widely used naloxone nasal spray sold by Emergent BioSolutions. However, it is unclear when the generic will be available as Teva is tied up in a legal battle with Narcan's manufacturer.
Naloxone also can be administered intravenously. Generic versions of the injectable naloxone have been available for years in healthcare settings, but the nasal spray versions can be used by those without medical training, including civilians and first responders.